- by Aayushi PratapAs Pfizer pulls a candidate from the market, Lilly expects its pill to get approved next year
- by Laurel OldachDrugmakers sort through many modalities to find the best match for their target proteins
- by Bethany HalfordCompound spurs neuron growth without causing hallucinations in mice
- by Ed Griffen, special to C&EN, and Pascale Boulet, special to C&ENWe want wide, fast, and affordable access for our new antiviral. It might sound counterintuitive, but a patent will help us do that
- by Bethany HalfordStructures unveiled during first-time disclosures symposium
- by Aayushi PratapCime Therapeutics focuses on synthesizing compounds for targets implicated in cancers
- by Sarah BranerPretzel Therapeutics’ polymerase stabilizers could treat mitochondrial DNA-based diseases
- by Aayushi PratapCime Therapeutics focuses on synthesizing compounds for targets implicated in cancers
- by Max BarnhartLariocidin is a lasso peptide that interferes with bacterial ribosomes and is nontoxic to human cells
- by Rowan WalrathResearchers still nervous about funding status
Making chemistry accessible and relevant.